- CONDITION CENTERS
Zydus Pharmaceuticals (USA) Inc is the US generic drug division of a much larger, India-based company known as Zydus Cadila Healthcare. Zydus Cadila is a global, fully integrated pharmaceutical company with 9,000 employees and a presence in 50 countries. Zydus is committed to growing its presence around the world and in the United States.
Zydus Cadila has been achieving this goal both through acquisitions and organic growth. Over the last 4 years, it has acquired companies in France, Japan, Brazil, and, most recently, in Spain and South Africa. Its vision is to be a leading global health care provider by 2010.
While Zydus Cadila continues to focus on the domestic market in India, it is growing rapidly in key regulated global generic markets, such as the United States, Europe, and Latin America. As the fourth largest pharmaceutical company in India, Zydus is well positioned to meet the needs of today's generic pharmaceutical marketplace and is forging relationships as a strategic sourcing manufacturer. What sets the company apart is a never-ending commitment to innovation and building a strong product pipeline, with a focus on high-quality, affordable products that will deliver the most value to the company as well as customers.
Zydus Cadila's manufacturing and development history spans more than 50 years. Its FDA-approved, 40-acre Moraiya plant is India's largest finished dosage plant under one roof. The breadth of the company's product form capability?tablets, hard and soft gelatin capsules, parenterals, and metered dose inhalers?sets it up to be "The Global Sourcing Partner of Choice."
Three technology centers all work together to develop the best quality products now and for the future. Zydus is also one of India's largest active pharmacecutical ingredient manufacturers, with 2 of its facilities FDA-approved and supporting many of its generic formulations.
Joe Renner, CEO of the US division, envisions a US generic marketplace where manufacturers and customers come together in the sourcing of generic products earlier on in the continuum of product management, in order to maximize the risk?reward profiles and deliver maximum value to all parties involved.
Zydus Pharmaceuticals (USA) Inc continues to grow; to date, the company has filed 60 drug master files, received 38 Abbreviated New Drug Application (ANDA) final and tentative approvals, and has 39 ANDAs pending approval with the FDA.
The company has had 4 successful "Day One" patent expiration launches: ribavirin tablets, meloxicam, carvedilol, and venlafaxine tablets; it also has more than 126 SKUs commercially available. Zydus again this year has been named by IMS Health as one of the fastest-growing pharmaceutical companies, based on total prescriptions dispensed.
Zydus' success to date is predicated upon its outstanding customer service, expanding generic portfolio, and dedication to being vertically integrated on many finished dosage forms. Its strong US management team has more than 40 years of experience in the US generic marketplace.
Recent approvals include venlafaxine tablets, bioequivalent to Pfizer's Effexor; dipyridamole tablets, bioequivalent to Boehringer Ingelheim's Persantine, and haloperidol tablets (5 mg, 10 mg, and 20 mg), bioequivalent to Ortho-McNeil's Haldol.
Zydus is poised to continue its tremendous growth, with its low-cost production, R&D/legal/regulatory capabilities for product development, and, most importantly, customer focus. Clearly, Zydus Cadila and its worldwide divisions are setting themselves up to be known as "The Global Sourcing Partner of Choice."
To learn more about Zydus Pharmaceuticals, visit www.zydususa.com.